Skip to content

EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522985-60-00
Enrollment
34
Registered
2026-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Brief summary

The primary endpoint is intracranial progression-free survival per RANO-BM criteria based on local assessment. It is defined as the time interval between the date of randomization and the date of intracranial progression or death, whichever occurs first.

Detailed description

Intracranial progression-free survival according to RANO-BM criteria based on retrospective central review, Time to next CNS intervention (TNCI), Overall Survival (OS), Intracranial overall response rate (icORR) based on RANO-BM criteria as per local assessment (in the upfront systemic therapy arm), The occurrence of any grade and grade ≥ 3 adverse events according to CTCAE v5.0, Cerebral (symptomatic) radio necrosis rate (in patients receiving SRS/FSRT during the course of treatment)., Duration of intracranial response as per local assessment.

Interventions

DRUGCarboplatin 10 mg/ml Concentrate for Solution for Infusion
DRUGivonescimab
DRUGNaveruclif 5 mg/ml powder for dispersion for infusion

Sponsors

European Organisation For Research And Treatment Of Cancer
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is intracranial progression-free survival per RANO-BM criteria based on local assessment. It is defined as the time interval between the date of randomization and the date of intracranial progression or death, whichever occurs first.—

Secondary

MeasureTime frame
Intracranial progression-free survival according to RANO-BM criteria based on retrospective central review, Time to next CNS intervention (TNCI), Overall Survival (OS), Intracranial overall response rate (icORR) based on RANO-BM criteria as per local assessment (in the upfront systemic therapy arm), The occurrence of any grade and grade ≥ 3 adverse events according to CTCAE v5.0, Cerebral (symptomatic) radio necrosis rate (in patients receiving SRS/FSRT during the course of treatment)., Duration of intracranial response as per local assessment.—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 21, 2026